• First amyloid plaque deposition around 6 months, numerous by 12 months • Absent tangles but hyper-phosphorylated tau present • Absent or minimal neuronal loss • Cognitive impairment as early as 6 months and widespread by 12 months (Hsiao et al., 1996) TgCRND8 (Mucke et al., 2000) APP/PS1
• APP (KM670/671NL; Swedish mutation) • PSEN1 (L166P) • Promoter: Thy1
• Amyloid deposition first at 1.5 months and progresses with age • Phosphorylated tau-positive neuritic process around plaques • Modest neuronal loss in dentate gyrus at 17 months • Cognitive impairments at 7-8 months (Radde et al., 2006) 3xTg
• APP (KM670/671NL; Swedish mutation) • PSEN1 (M146V) • MAPT (P301L) • Promoter: Thy1.2
• Amyloid deposition first at 6 months and progresses with age • No tau pathology at 6 months, and tau immunoreactivity extensive by 12 months • Unknown cell loss • Cognitive impairment as early as 4 months prior to formation of plaques and tangles (Oddo et al., 2003) Tg4510
• MAPT (P301L) • Transgene downstream of TRE and driven by tTA under the control of CaMKII-α promoter
• No amyloid plaques • Tangles present at 4 months • Significant neuronal and brain volume loss • Cognitive impairment starting as early as 2.5 months (Santacruz et al., 2005) 
